Mavri-Damelin Demetra, Eaton Simon, Damelin Leonard H, Rees Myrddin, Hodgson Humphrey J F, Selden Clare
The UCL Institute of Hepatology, Hampstead Campus, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, UK.
Int J Biochem Cell Biol. 2007;39(3):555-64. doi: 10.1016/j.biocel.2006.10.007. Epub 2006 Oct 21.
A possible cell source for a bio-artificial liver is the human hepatblastoma-derived cell line HepG2 as it confers many hepatocyte functions, however, the urea cycle is not maintained resulting in the lack of ammonia detoxification via this cycle. We investigated urea cycle activity in HepG2 cells at both a molecular and biochemical level to determine the causes for the lack of urea cycle expression, and subsequently addressed reinstatement of the cycle by gene transfer. Metabolic labelling studies showed that urea production from 15N-ammonium chloride was not detectable in HepG2 conditioned medium, nor could 14C-labelled urea cycle intermediates be detected. Gene expression data from HepG2 cells revealed that although expression of three urea cycle genes Carbamoyl Phosphate Synthase I, Arginosuccinate Synthetase and Arginosuccinate Lyase was evident, Ornithine Transcarbamylase and Arginase I expression were completely absent. These results were confirmed by Western blot for arginase I, where no protein was detected. Radiolabelled enzyme assays showed that Ornithine Transcarbamylase functional activity was missing but that Carbamoyl Phosphate Synthase I, Arginosuccinate Synthetase and Arginosuccinate Lyase were functionally expressed at levels comparable to cultured primary human hepatocytes. To restore the urea cycle, HepG2 cells were transfected with full length Ornithine Transcarbamylase and Arginase I cDNA constructs under a CMV promoter. Co-transfected HepG2 cells displayed complete urea cycle activity, producing both labelled urea and urea cycle intermediates. This strategy could provide a cell source capable of urea synthesis, and hence ammonia detoxificatory function, which would be useful in a bio-artificial liver.
一种可能用于生物人工肝的细胞来源是源自人类肝母细胞瘤的细胞系HepG2,因为它具有许多肝细胞功能。然而,其尿素循环无法维持,导致无法通过该循环进行氨解毒。我们在分子和生化水平上研究了HepG2细胞中的尿素循环活性,以确定尿素循环表达缺失的原因,随后通过基因转移恢复该循环。代谢标记研究表明,在HepG2条件培养基中无法检测到由15N-氯化铵产生的尿素,也无法检测到14C标记的尿素循环中间产物。HepG2细胞的基因表达数据显示,尽管三种尿素循环基因——氨甲酰磷酸合成酶I、精氨琥珀酸合成酶和精氨琥珀酸裂解酶的表达明显,但鸟氨酸转氨甲酰酶和精氨酸酶I的表达完全缺失。精氨酸酶I的蛋白质印迹证实了这些结果,未检测到蛋白质。放射性标记酶分析表明,鸟氨酸转氨甲酰酶的功能活性缺失,但氨甲酰磷酸合成酶I、精氨琥珀酸合成酶和精氨琥珀酸裂解酶在功能上的表达水平与培养的原代人肝细胞相当。为了恢复尿素循环,用CMV启动子下的全长鸟氨酸转氨甲酰酶和精氨酸酶I cDNA构建体转染HepG2细胞。共转染的HepG2细胞显示出完整的尿素循环活性,产生标记尿素和尿素循环中间产物。这种策略可以提供一种能够合成尿素,从而具有氨解毒功能的细胞来源,这在生物人工肝中会很有用。